Ari Vander Walde

Aug 17, 2023 | nature.com | Ari Vander Walde |Katie Campbell |Philip O. Scumpia |Alexandra Ikeguchi |Bartosz Chmielowski |Kim Margolin | +3 more

AbstractIn this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone.

Feb 11, 2023 | frontiersin.org | Ari Vander Walde

Skin cancer is the most commonly occurring cancer worldwide with two major subcategories of melanoma and non-melanoma (1). Conventionally, skin cancers are treated with surgery and/or radiotherapy, however, if not diagnosed and treated early these malignancies can progress to locally advanced or metastatic stages.